Four things to know about the company’s second-quarter financial performance:
- Medtronic saw a 3 percent dip in reported revenue, but saw a 2 percent increase in organic growth.
- Medtronic brought in $2.19 billion from its neuroscience portfolio
- The company reported a GAAP diluted earnings per share of $0.32, a decrease of 67 percent, and a non-GAAP diluted earnings per share of $1.30, a decrease of 2 percent.
- The company said in a Nov. 22 news release that it expects to see more organic revenue growth during the second half of the fiscal year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
